LCI : Analysis & Opinions

  1. OncoGenex's AFFINITY on Track, Passes Futility Analysis - Analyst ...

    January 19, 2015
    OncoGenex Pharmaceuticals, Inc. (OGXI) announced that the phase III AFFINITY study on custirsen has passed the interim futility ...
  2. UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst ...

    January 19, 2015
    UCB S.A. (UCBJF) and Neuropore Therapies Inc. entered into a collaboration agreement for the development and commercialization ...
  3. Cempra Reports Positive Results on Antibiotic Solithromycin - ...

    January 5, 2015
    Cempra, Inc. (CEMP) announced positive top-line results from a phase III study on pipeline candidate solithromycin. Cempra ...
  4. NephroGenex Hits 52-Week High on Pyridorin Safety Data - Analyst ...

    January 2, 2015
    NephroGenex, Inc. (NRX) announced that its diabetic nephropathy candidate, Pyridorin, was found to be safe in a cardiac safety ...
  5. OncoGenex to End Deal with Teva & Regain Custirsen Rights - Analyst ...

    December 31, 2014
    OncoGenex Pharmaceuticals, Inc. (OGXI) executed an initial agreement to regain all rights to custirsen from Teva and end ...
  6. Cerus Corporation Reports Phase II Red Blood Cells Data - Analyst ...

    December 29, 2014
    Cerus Corporation (CERS) announced that its phase II study on red blood cells when treated with the INTERCEPT blood system ...
  7. ImmunoGen/Roche's Kadcyla Fails in Study, Shares Plunge - Analyst ...

    December 22, 2014
    ImmunoGen (IMGN) and partner Roche's Kadcyla failed to meet the primary endpoint in a phase III study conducted in HER2-positive ...
  8. UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst ...

    December 18, 2014
    UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for ...
  9. OncoGenex's Pancreatic Cancer Study Fully Enrolled - Analyst ...

    December 17, 2014
    OncoGenex Pharmaceuticals, Inc. (OGXI) has completed enrolling patients in its phase II Rainier study on apatorsen for previously ...
  10. Salix Gains on Destocking Initiatives, Gives 2-Year Outlook - ...

    December 17, 2014
    Salix (SLXP) expects to resolve its inventory situation a year ahead of schedule and now expects a FDA response on Xifaxan ...
  11. The Small-Cap Guru Bought These 3 Stocks

    August 31, 2014
    Like many cash-strapped investors just starting out, I was convinced I could “maximize” my tiny investment account ...
  12. Small-Cap Guru Chuck Royce Just Loaded Up On These 3 Stocks

    August 31, 2014
    Like many cash-strapped investors just starting out, I was convinced I could “maximize” my tiny investment account ...
  13. Lannett Beats, Ups Guidance - Analyst Blog

    February 11, 2013
    Lannett Company, Inc. (LCI) reported second quarter fiscal 2013 earnings of 10 cents per share, above the Zacks Consensus ...
Trading Center